ERBB2 and neoplasm: Patients with ER-positive tumours had a median survival time of 25 months (Her2-positive or -negative).[20] Our data were in agreement with published literature that stated that ER-negative tumours had earlier recurrence risks and shorter survival time after recurrence, and we demonstrated that the peak hazard of mortality was 4 years after diagnosis in ER-positive patients and 2 years in ER-negative patients.